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Heterocyclic antidepressants were the mainstay of antidepressant treatment from
their inception in the late 1950’s until the mid-1980’s. The development of synthetic he-
terocyclic compounds as antidepressant, sedative or analgesic agents progressed consid-
erably during the past decade (1–3). In recent years, the role of antidepressant drugs in
the management of different pain syndromes has elicited considerable interest (4, 5). Py-
rimidine derivatives possessing anti-inflammatory, antidepressant and analgesic activi-
ties have been reported in literature (6–8). Over the past few years, our research group
was conducting a comprehensive program towards the synthesis of thiophenes and
their fused derivatives (9–12). The importance of such compounds is based on their use
as anti-flammatory (13, 14), anti-protozoal (15), and antitumor agents (16), templates for
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serine protease inhibition (17) and alternate substrate inhibitors of cholesterol eastrase
(18). In view of all these observations, we report here in on the use of 2-amino-4,5,6,7-
-tetrahydrobenzobthiophene derivatives (1a,b) (19) in the synthesis of novel ben-
zobthienopyrimidine derivatives. The systemic anti-depressant, sedative or analgesic
activities of the newly synthesized compounds were also investigated.
EXPERIMENTAL
Synthetic methods, analytical and spectral data
Melting points were determined on an electrothermal apparatus (Büchi 535, Swit-
zerland) in an open capillary tube and are uncorrected. Elemental analyses were deter-
mined on a Yanaco CHN Corder elemental analyzer (Japan). IR spectra (n cm–1) were re-
corded in KBr pellets on a PA-9721 IR spectrophotometer (Shimadzu, Japan). 1H NMR
and 13C NMR spectra were obtained on a Jeol 300 MHz (Japan) spectrometer in DMSO-
-d6 as solvent, using TMS as internal reference and chemical shifts (d) are expressed in
ppm. Mass spectra were recorded on Kratos (75e V) MS equipment (Germany). Elemen-
tal analyzes were performed on a Yanaco CHN Corder elemental analyzes (Japan).
The analytical and spectral data of the newly synthesized products are presented in
Tables I and II, respectively. The pharmacological data are given in Tables III, IV and V.
Compounds 2a and 2b were synthesized according to our recently published work
(20).
3-Cyano-2-(N-ethoxycarbonylthiouryl)-4,5,6,7-tetrahydrobenzobthiophene (2a) and ethyl
2-(N-ethoxycarbonylthiouryl)-4,5,6,7-tetrahydrobenzobthiophen-3-carboxylate (2b)
General procedure. – To a solution of either 1a (1.78 g, 0.01 mol) or 1b (2.25 g, 0.01
mol) in 1,4-dioxan (30 mL), ethoxycarbonyl isothiocyanate (1.31 g, 0.01 mol) prepared
by adding ammonium isothiocyanate (0.01 mol) to a solution of ethyl chloroformate
(0.01 mol) in 1,4-dioxan (20 mL) and heating for 1/2 h followed by isolation of the by-
product, ammonium chloride was added. The whole reaction mixture, in each case, was
stirred at room temperature overnight and the solid product formed upon pouring onto
ice/water was collected by filtration to give either 2a or 2b, crystallized from acetic acid.
Ethyl 1-imino-3-thioxo-4H-6,7,8,9-tetrahydrobenzobthieno2,3-dpyrimidin-2-carboxylate (3a)
and ethyl 1-oxo-3-thioxo-4H-6,7,8,9-tetrahydrobenzobthieno2,3-dpyrimidin-2-carboxylate (3b)
General procedure. – A suspension of either 2a (3.09 g, 0.01 mol) or 2b (3.56 g, 0.01
mol) in sodium ethoxide (0.01 mol) prepared by dissolving sodium metal (0.23 g, 0.01
mol) in absolute ethanol (40 mL) was heated in a boiling water bath for 6 h and then left
to cool. The solid product, formed upon pouring onto ice/water containing hydrochlo-
ric acid (to pH = 6), was collected by filtration to give either 3a, crystallized from 1,4-dio-
xane or 3b, crystallized from ethanol.
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3-Cyano-2-(N-phenylaminocarbonylthiourayl-4,5,6,7-tetrahydrobenzobthiophene (4a) and
ethyl2-(N-phenylaminocarbonylthiourayl-4,5,6,7-tetrahydrobenzobthiophen-3-carboxylate (4b)
General procedure. – To a dry solid of either 2a (3.09 g, 0.01 mol) or 2b (3.56 g, 0.01
mol), aniline oil (0.94 g, 0.01 mol) was added. The reaction mixture was heated in an oil
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CH2), 2225 (CN), 1687
(CO), 1638 (C=C),
1205–1196 (C=S)
1.61 (t, 3H, J = 7.02 Hz,
CH3), 2.14–2.16 (m, 4H,
2CH2), 2.23–2.26 (m, 4H,
2CH2), 4.11 (s, 1H, NH),
4.24 (q, 2H, J = 7.02, CH2),
8.32 (s, 1H, NH)
14.88 (ester CH3), 20.0,
23.3, 23.9, 24.7 (4CH2),
60.5 (ester CH2), 118.8
(CN), 122.3, 136.7, 135.6,
140.8 (thiophene-C), 154.7




CH2), 1690, 1685 (2
CO), 1636 (C=C),
1205–1196 (C=S)
1.62, 1.65 (2t, 6H, 2 CH3),
2.16–2.19 (m, 4H, 2CH2),
2.25–2.29 (m, 4H, 2CH2),
4.10 (s, 1H, NH), 4.22, 4.25
(2q, 4H, 2 CH2), 8.30 (s, 1H,
NH)
14.87, 16.58 (two ester
CH3), 20.1, 23.5, 23.6, 24.4
(4CH2), 60.6, 62.7 (two ester
CH2), 118.6 (CN), 122.1,










1.36 (t, 3H, J = 7.66 Hz,
CH3), 1.69–1.72 (m, 4H,
2CH2), 2.20–2.23 (m, 4H,
2CH2), 4.13 (s, 1H, NH),
4.20 (q, 2H, J = 7.66 Hz,
CH2), 8.26 (s, 1H, NH)
13.8 (ester CH3), 23.3, 23.9,
24.7 (4CH2), 52.7
(ester CH2), 121.3, 134.3,
136.9, 147.9.1 (thiophene-C),
159.8 (C=O), 164.7 (C=N),
179.5 (C=S)
309
3b 3456–3336 (NH), 2980,
2890 (CH3, CH2),
1693, 1685 (2 CO),
1636 (C=C), 1204–1190
(C=S)
1.38 (t, 3H, J = 7.21 Hz,
CH3), 1.66–1.70 (m, 4H,
2CH2), 2.22–2.26 (m, 4H,
2CH2), 4.22 (s, 1H, NH),





2218 (CN), 1682 (CO),
1637 (C=C)
1.64–1.68 (m, 4H, 2CH2),
2.25–2.28 (m, 4H, 2CH2),
4.33, 5.42 (2s, 2H, 2NH),
7.03–7.35 (m, 5H, C6H5),
8.81 (s, 1H, NH)
20.3, 22.3, 23.9, 24.9
(4CH2), 118.6 (CN), 120.8,
121.7, 122.8, 124.7, 137.9
(phenyl C), 130.7, 132.2,
138.7, 144.8 (thiophene C),





CH2), 1692, 1686 (2
CO), 1637 (C=C)
1.34 (t, 3H, J = 6.77 Hz,
CH3), 1.66–1.72 (m, 4H,
2CH2), 2.23–2.27 (m, 4H,
2CH2), 4.22 (q, 2H, J = 6.77
Hz, CH2), 4.30, 5.30 (2s, 2H,
2NH), 7.33–7.42 (m, 5H,








1.68–1.70 (m, 4H, 2CH2),
2.25–2.29 (m, 4H, 2CH2),
4.32, 5.36 (2s, 2H, 2NH),
7.22–7.36 (m, 5H, C6H5),
9.05 (s, 1H, NH)
356
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5b 3462–3336 (2 NH),
3049 (CH-aromatic),
1693, 1685 (2 CO),
1637 (C=C), 1203–1196
(C=S)
1.65–1.74 (m, 4H, 2CH2),
2.22–2.27 (m, 4H, 2CH2),
4.36 (s, 1H, NH), 7.28–7.38








1.65–1.70 (m, 4H, 2CH2),
2.22–2.31 (m, 4H, 2CH2),
4.68 (s, 2H, CH2), 7.33–7.39
(m, 10H, 2C6H5), 8.38, 8.94
(2s, 2H, 2NH)
20.4, 22.3, 24.4, 24.5
(4CH2), 128.6 (CN), 120.6,
121.9, 122.5, 124.2, 138.4,
139.5, 140.3 (two phenyl
C), 130.4, 132.8, 134.8,
149.8 (thiophene C), 156.8,
160.3 (2 CO), 168.7 (C=O)
474




1.66–1.73 (m, 4H, 2CH2),
2.24–2.28 (m, 4H, 2CH2),
4.58 (s, 2H, CH2), 7.31–7.40
(m, 10H, 2 C6H5), 8.33 (s,
1H, NH)
475
7a 3456–3318 (2 NH),
3058 (CH-aromatic),
2978, 2869 (CH3,
CH2), 1690, 1688 (2
CO), 1660 (C=N),
1636 (C=C)
1.33 (t, 3H, J = 7.11 Hz,
CH3), 1.64–1.71 (m, 4H,
2CH2), 2.25–2.32 (m, 4H,
2CH2), 4.21 (q, 2H, J = 7.11
Hz, CH2), 4.92 (s, 2H, CH2),
7.26–7.37 (m, 5H, C6H5),
8.26, 8.36 (2s, 2H, 2NH)
422
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2CH2), 2.24–2.36 (m, 4H,
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Hz, CH2), 4.86 (s, 2H, CH2),
7.28–7.40 (m, 5H, C6H5),







1.65–1.70 (m, 4H, 2CH2),
2.22–2.31 (m, 4H, 2CH2),
2.88 (s, 1H, NH), 4.46 (s,
2H, NH2), 6.58 (s, 1H, NH),
7.31–7.39 (m, 5H, C6H5),
8.21 (s, 1H, NH).
20.9, 22.6, 24.4, 24.9
(4CH2), 120.8, 121.7, 122.8,
123.5, 134.8 (phenyl C),
133.5, 133.7, 134.4, 147.9,
158.4 (thiophene, pyrimi-








1.63–1.68 (m, 4H, 2CH2),
2.24–2.36 (m, 4H, 2CH2),
2.87, (s, 1H, 1NH), 6.55 (s,
1H, NH), 7.26–7.38 (m,





matic), 1691, 1688 (2
CO), 1657 (C=N),
1644 (C=C)
1.60–1.66 (m, 4H, 2CH2),
2.20–2.32 (m, 4H, 2CH2),
2.87 (s, 1H, NH), 4.68 (s,
2H, NH2), 7.32–7.37 (m, 5H,
C6H5), 8.20 (s, 1H, NH)
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bath (140 °C) for 1 h. Then, it was left to cool and the remaining product was triturated
with diethyl ether and the formed solid product was collected by filtration to give either
4a or 4b, crystallized from acetic acid.
1-Imino-2-phenylaminocarbonyl-4H-3-thioxo-6,7,8,9-tetrahydrobenzobthieno2,3-dpyrimidi-
ne (5a) and 1-oxo-2-phenylaminocarbonyl-4H-3-thioxo-6,7,8,9-tetrahydrobenzobthieno-
-2,3-dpyrimidine (5b)
Method A. – A suspension of either 3a (3.56 g, 0.01 mol) or 3b (4.03 g, 0.01 mol), in
sodium ethoxide/ethanol solution prepared by dissolving sodium metal (0.46 g, 0.02
mol) in absolute ethanol (60 mL) was heated in a boiling water bath for 12 h. The solid
product formed upon pouring onto ice/water containing hydrochloric acid (till pH 6)
was collected by filtration to give either 5a or 5b, crystallized from DMF.
Method B. – To the dry solid of either 3a (3.09 g, 0.01 mol) or 3b (3.10 g, 0.01 mol),
aniline oil (0.94 g, 0.01 mol) was added. It was reaction mixture was heated in an oil bath
(140 °C) for 1 h. It was left to cool and the remaining product was triturated with diethyl
ether and the formed solid product was collected by filtration.
3-Benzoylmethylsulphido-1-imino-2-phenylaminocarbonyl-6,7,8,9-tetrahydrobenzob-thieno2,3-d-
pyrimidine (6a), 3-benzoylmethylsulphido-1-oxo-2-phenylaminocarbonyl-6,7,8,9-tetrahydroben-
zobthieno2,3-dpyrimidine (6b), 1-imino-2-phenylaminocarbonyl-3-(ethyl acetatosulfyl)-6,7,-
8,9-tetrahydrobenzobthieno2,3-dpyrimidine (7a) and 1-oxo-2-phenylamino-carbonyl-3-(ethyl-
acetatosulfyl)-6,7,8,9-tetrahydrobenzobthieno2,3-dpyrimidine (7b)
General procedure. – To a solution of either 5a (3.56 g, 0.01 mol) or 5b (3.57 g, 0.01
mol) in 1,4-dioxane (40 mL), either -bromoacetophenone (2.0 g, 0.01 mol) or ethyl chlo-
roacetate (1.22 g, 0.01 mol) was added. The reaction mixture, in each case, was heated
under reflux for 2 h, then poured onto ice/water containing a few drops of sodium hy-
droxide (to pH 6) and the formed solid product was collected by filtration to give either




thieno2,3-dpyrimidine (8c) and 3-phenylhydrazino-2-phenylaminocarbonyl-1-oxo-6,7,8,9-te-
trahydrobenzobthieno2,3-dpyrimidine (8d)
General procedure. – To a solution of either 7a (4.42 g, 0.01 mol) or 7b (4.43 g, 0.01
mol) in 1,4-dioxane (40 mL), either hydrazine hydrate (0.5 g, 0.01 mol) or phenylhydra-
zine (1.08 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under
reflux for 6 h, then poured onto ice/water containing hydrochloric acid (to pH 6) and
the formed solid product was collected by filtration to give either 8a or 8b, crystallized
from 1,4-dioxane or 8c or 8d, crystallized from DMF.
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8d 3348–3320 (3NH),
3058 (CH-aromatic),
1684, 1680 (2 CO),
1662 (C=N), 1637
(C=C)
1.62–1.69 (m, 4H, 2CH2),
2.22–2.30 (m, 4H, 2CH2),
2.90 (s, 1H, NH), 7.31–7.42




Swiss albino mice of either sex, weighing 20–25 g, aged 6–8 weeks, were supplied
by the Animal House at National Research Centre (Giza, Egypt). Animals were maintai-
ned under 12/12 h light/dark cycle at 20  2 and fed the standard laboratory diet and
water ad libitum. In accordance with the recommendations for the proper care and use of
laboratory animals (NIH publication No. 85–23, revised 1985), groups of 6 mice for
group were used in all experiments.
Screening for antidepressant activity
Porsolt’s forced-swimming test. – Each mouse was placed individually in a glass cylin-
der (diameter 12 cm, height 24 cm) filled with water to a height of 12 cm. Water tempe-
rature was maintained at 22–23 °C. The animal was forced to swim for 6 min and the du-
ration of immobility was measured. The mouse was considered to be immobile when it
stopped struggling and moved only to remain floating in water, keeping its head above
water. The floating time, which was the measure of despair (21), was recorded 60 min af-
ter treatment with each drug (15 or 30 mg kg–1, i.p.), saline or imipramine (15 mg kg–1,
i.p.). Test compounds were dissolved using a few drops of Tween 80 and further dilu-
tions were done using saline to get the necessary doses. The negative control was the ve-
hicle solution (Tween 80 in saline).
Screening for sedative effect
Mice were observed in a commercially available motor activity apparatus (Ugo Basel,
Italy) in which locomotor and exploratory activity could be monitored. In these experimen-
ts, each mouse was intraperitoneally injected with the drug (30 mg kg–1) and 30 min later it
was placed in the activity monitor in which activity was monitored for 6 min.
Screening for analgesic effect
Acetic acid-induced writhing was performed for separate groups of 6 mice each, to
which i.p. vehicle, compounds 2a, 3a, 5b, 6a and 8b (15 and 30 mg kg–1) or indomethacin
were administered (20 mg kg–1). After 30 min pretreatment interval, an i.p. injection of
0.6% acetic acid was administered (22). Each mouse was then placed in an individual
clear plastic observational chamber and the total number of writhes (abdomen constric-
tion, trunk twisting and extension of hind legs) made by each mouse was counted for 30
min after acetic acid administration.
Statistics
Data are presented as mean ± SEM. Data were analyzed by ANOVA followed by the
Duncan and multiple group comparison test.
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RESULTS AND DISCUSSION
Chemistry
The reaction of 2-amino-4,5,6,7-tetrahydrobenzobthiophene derivative 1a,b with
ethoxycarbonylisothiocyanate in 1,4-dioxane at room temperature gave the N-ethoxycar-
bonylthiourea derivatives 2a and 2b, respectively. The structures of compounds 2a,b
were based on analytical and spectral data. Thus, the 1H NMR spectrum of 2a showed
the presence of a triplet at d 1.61 ppm corresponding to the ester CH3 group, a multiplet
at d 2.14–2.16 and 2.23–2.26 ppm corresponding to the four CH2 groups of cyclohexene
8
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Sheme 1
ring, two singlets at d 4.11 and 8.32 for the two NH groups and a quartet at d 4.24 ppm
for the ester CH2 group. The reactions of isothiocyanates with NH2 compounds were re-
ported earlier (23). Compounds 2a,b underwent ready cyclization when heated in so-
dium ethoxide/ethanol solution in a boiling water bath to give the tetrahydrobthieno
2,3-dpyrimidine derivatives 3a and 3b, respectively.
The reaction of 2a,b with aniline in an oil bath (at 140 °C) gave the anilide derivati-
ves 4a and 4b, respectively. Structures of compounds 4a,b were based on the obtained
analytical and spectral data (see experimental section). In the reaction of 2b, aniline re-
acts with the ethyl N-carboxylate rather than the ethyl carboxylate group attached to
C-thiophene based on the cyclization of 4b into 5b via ethanol elimination. Moreover,
formation of the same cyclized product via another reaction route was noted. Thus, com-
pounds 4a and 4b underwent ready cyclization when heated in sodium ethoxide/etha-
nol solution in a boiling water bath to give the 4,5,6,7-tetrahydrobenzobthieno2,3-d-
pyrimidine derivatives 5a and 5b, respectively. Structures of the latter products were es-
tablished on the basis of analytical and spectral data and on their synthesis using an-
other reaction route. Thus, the reaction of either 3a or 3b with aniline oil at 140 °C gave
the same products 5a and 5b, respectively (m.p., mixed m.p. and fingerprint IR spec-
trum) (Scheme 1).
The reaction of either compound 5a or 5b with -bromoacetophenone in 1,4-dioxa-
ne gave the thioether-tetrahydrobenzobthieno2,3-dpyrimidine derivatives 6a and 6b,
respectively. Structures of the latter products were based on analytical and spectral data.
The 1H NMR spectrum of 6a showed the presence of two multiplets with d 1.65–1.70
ppm and 2.22–2.31 ppm for the 4 CH2 groups, a singlet with d 4.68 ppm for the side
9
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Table III. Effect of tested compounds on the duration of immobility in
Porsolt’s forced-swimming test
Treatment/compd. Duration of immobility (s)a
Saline 289.9  7.1
Imipramine (15 mg kg–1) 237.0  14.0b
2a (15 mg kg–1) 279.7  11.4
2a (30 mg kg–1) 265.5  15.8
3a (15 mg kg–1) 269.3  9.6
3a (30 mg kg–1) 266.1  10.3
5b (15 mg kg–1) 271.7  8.5
5b (30 mg kg–1) 266.7  17.6
6a (15 mg kg–1) 286.8  7.8
6a (30 mg kg–1) 273.3  13.6
8b (15 mg kg–1) 283.9  11.8
8b (30 mg kg–1) 301.0  9.4
a Mean  SEM (n = 6).
b Significant difference vs. saline-treated control group (p < 0.05).
chain CH2 group, a multiplet with d 7.33–7.39 ppm for the two phenyl groups and two
singlets with d 8.38 and 8.94 ppm corresponding to two NH groups. On the other hand,
the reaction of either 5a or 5b with ethyl chloroacetate gave the thioether derivatives 7a
and 7b, respectively. The spectral data of the latter are consistent with the proposed
structures (Tables I and II). The reaction of either compound 7a or 7b with either hydra-
zine hydrate or phenylhydrazine afforded the corresponding 2-hydrazino-4,5,6,7-tetra-
hydrobenzobthieno2,3-dpyrimidine derivatives 8a-d, respectively (Scheme 2). The
analytical and spectral data of the latter products agree well with the proposed structu-
res (Tables I and II).
Screening for antidepressant activity
After 60 min of i.p. administration, some compounds (2a, 3a and 5b) showed mild,
non-significant antidepressant activity at high doses and were found active, compared
with negative control group. The other compounds failed to display antidepressant pro-
perties in the swimming test (Table III).
10
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Screening for sedative activity
No sedative effect could be observed in mice treated with compounds 2a, 5b, 6a and
8b; even more exploratory movements compared to the saline treated group were obser-
ved (Table IV).
All tested compounds at the two doses (15 or 30 mg kg–1), except for the lower dose
of 8b, significantly reduced the number of abdominal writhes induced by i.p. injection of
11
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Table IV. Effect of tested compounds on the number of exploratory
movements in micea
Treatment/compd. Number of movementsb
Saline 27.8  2.3
2a (30 mg kg–1) 36.3  3.9c
3a (30 mg kg–1) 25.0  1.9
5b (30 mg kg–1) 51.3  3.0c
6a (30 mg kg–1) 39.3  4.4c
8b (30 mg kg–1) 63.5  3.9c
a Number of movements in 6 minutes.
b Mean  SEM (n = 6).
c Significant difference vs. saline-treated control group (p < 0.05).
Table V. Inhibition of abdominal constrictions caused by injection of acetic acida
Treatment/compd. Number Inhibition (%)
Saline 92.8  6.0 –
2a (15 mg kg–1) 44.8  4.0c 51.7
2a (30 mg kg–1) 2.5  0.29c 97.3
3a (15 mg kg–1) 28.3  3.5c 69.5
3a (30 mg kg–1) 26.8  1.2c 71.7
5b (15 mg kg–1) 31.5  2.2c 66.1
5b (30 mg kg–1) 27.5  3.2c 70.4
6a (15 mg kg–1) 50.0  4.0c 46.1
6a (30 mg kg–1) 23.5  2.6c 74.7
8b (15 mg kg–1) 81.7  6.8 11.9
8b (30 mg kg–1) 57.3  4.1c 38.3
Indomethacin (20 mg kg–1) 50.3  5.4c 45.8
a Constriction during 30 min.
b Mean  SEM (n = 6).
c Significant difference vs. saline-treated control group (p < 0.05).
acetic acid in mice (Table V). Compound 2a was the most potent in this respect, inhibit-
ing the number of abdominal writhes by 97.3% at high dose (30 mg kg–1), compared to
saline as the negative control group. Meanwhile, compounds 6a, 3a and 5b at high doses
inhibited the number of abdominal writhes by 74.7, 71.7 and 70.4%, respectively. These
compounds, at low and high doses, were even more potent than indomethacin in this re-
spect.
From the structure-activity relationship viewpoint, the thiourea tetrahydrobenzo-
bthiophene derivative 2a has the strongest antidepressant and analgesic activity. Repla-
cement of ethoxycarbonylthiouryl side chain with fused pyrimidine moiety decreased
these activities in the other compounds. The presence of benzoylmethylsulphide side
chain attached to pyrimidine moiety in compound 6a increased its activity as analgesic
agent.
CONCLUSIONS
In this study, we have described efficient synthesis of novel benzobthienopyrimi-
dine derivatives derived from the thiourea derivatives of tetrahydrobenzobthiophenes
2a and 2b. The newly synthesized thiophene derivatives 2a, 3a, 5b, 6a and 8b showed
mild antidepressant and analgesic activity of various intensities. However, compound
2a had the strongest antidepressant and analgesic activity. Compounds 2a, 6a, 3a and 5b,
as analgesic agents, at low and high doses, were more potent than indomethacin.
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S A @ E T A K
Ispitivanje antidepresivnog, sedativnog i analgetskog djelovanja novih
fuzioniranih derivata tiofena
WAGNAT W. WARDAKHAN, OMAR M. E. ABDEL-SALAM i GAMAL A. ELMEGEED
U radu je opisana sinteza fuzioniranih derivata benzotiofena koji sadr`e heteroci-
kli~ki ostatak bitan za farmakolo{ko djelovanje. Tiourea derivati 2a,b dobiveni su re-
akcijom derivata tetrahidrobenzobtiofena 1a,b s etoksikarbonilizotiocijanatom. Iz njih
su dalje prire|eni anulirani derivati benzobtienopirimidina 3a,b. Spojevi 2a,b i 3a su
reakcijama heterociklizacije prevedeni u benzobtienopirimidine 5a,b-8a-c. Ispitivano je
antidepresivno, sedativno i analgetsko djelovanje novosintetiziranih derivata tiouree 2a
i benzobtienopirimidina 3a, 5b, 6a i 8b u dvije doze (15 ili 30 mg kg1 tjelesne mase).
Spojevi 2a, 3a i 5b pokazali su blago antidepresivno djelovanje u testu forsiranog pliva-
nja, dok sedativni u~inak nije pokazao niti jedan ispitivani spoj. Visceralna bol inducira-
na i.p. injekcijom octene kiseline u mi{eva zna~ajno je inhibirana sa svim spojevima, ali u
visokim dozama.
Klju~ne rije~i: tetrahidrobenzobtiofen, pirimidin, tiourea, antidepresiv, sedativ, analgetik
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